HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Compare relative returns, fundamentals, and sector rankings head-to-head.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Molecular Partners

Contributing Author

Recent Articles by Molecular Partners

May-30
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 MOLN GlobeNewswire
May-26
Molecular Partners to Present at TD Cowen's 7th Annual Oncology Innovation Summit MOLN GlobeNewswire
May-12
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 MOLN GlobeNewswire
May-04
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences MOLN GlobeNewswire
May-01
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling MOLN GlobeNewswire
Apr-19
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 MOLN GlobeNewswire
Apr-14
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting MOLN GlobeNewswire
Mar-23
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors MOLN GlobeNewswire
Mar-19
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes MOLN GlobeNewswire
Mar-17
Molecular Partners to Hold Three Poster Presentations at AACR 2026 MOLN GlobeNewswire
Mar-12
Molecular Partners Reports Highlights and Financial Results for Full Year 2025 MOLN -10.40% MOLN GlobeNewswire
Feb-26
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results MOLN GlobeNewswire
Feb-26
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics MOLN GlobeNewswire
Feb-02
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 MOLN +7.53% GlobeNewswire
Jan-11
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference MOLN GlobeNewswire
Dec-18
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference MOLN GlobeNewswire
Dec-11
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics MOLN GlobeNewswire
Dec-07
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting MOLN GlobeNewswire
Nov-12
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action MOLN GlobeNewswire
Nov-03
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 MOLN +12.42% GlobeNewswire
Nov-03
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting MOLN +12.42% GlobeNewswire
Oct-30
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 MOLN GlobeNewswire
Aug-25
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 MOLN +14.85% MOLN -7.71% GlobeNewswire
Aug-21
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics MOLN GlobeNewswire
Jun-22
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MOLN GlobeNewswire
Jun-11
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 MOLN +8.03% MOLN GlobeNewswire
Jun-10
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway MOLN GlobeNewswire
May-19
Molecular Partners to Present at Upcoming Investor Conferences MOLN GlobeNewswire
May-15
Molecular Partners Reports Financial Results and Highlights from Q1 2025 MOLN GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)